LDLori E. Dodd

Lori E. Dodd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lori E. Dodd has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mpox lesion counting with semantic and instance segmentation methods

    by Bohan Jiang, Andrew J. McNeil, Yihao Liu, David W. House, Placide Mbala-Kingebeni, Olivier Tshiani Mbaya, Tyra Silaphet, Lori E. Dodd, Edward W. Cowen, Veronique Nussenblatt, et al.

    PurposeMpox is a viral illness with symptoms similar to smallpox. A key clinical metric to monitor disease progression is the number of skin lesions. Manually counting mpox skin lesions is labor-intensive and susceptible to human error.ApproachWe previously developed an mpox lesion counting method based on the UNet segmentation model using 66 photographs from 18 patients. We have compared four additional methods: the instance segmentation methods Mask R-CNN, YOLOv8, and E2EC, in addition to a UNet++ model. We designed a patient-level leave-one-out experiment, assessing their performance using F1 score and lesion count metrics. Finally, we tested whether an ensemble of the networks outperformed any single model.ResultsMask R-CNN model achieved an F1 score of 0.75, YOLOv8 a score of 0.75, E2EC a score of 0.70, UNet++ a score of 0.81, and baseline UNet a score of 0.79. Bland-Altman analysis of lesion count performance showed a limit of agreement (LoA) width of 62.2 for Mask R-CNN, 91.3 for YOLOv8, 94.2 for E2EC, and 62.1 for UNet++, with the baseline UNet model achieving 69.1. The ensemble showed an F1 score performance of 0.78 and LoA width of 67.4.ConclusionsInstance segmentation methods and UNet-based semantic segmentation methods performed equally well in lesion counting. Furthermore, the ensemble of the trained models showed no performance increase over the best-performing model UNet, likely because errors are frequently shared across models. Performance is likely limited by the availability of high-quality photographs for this complex problem, rather than the methodologies used.

  • Platform Trials — Beware the Noncomparable Control Group

    by Lori E. Dodd, Boris Freidlin, Edward L. Korn

    The coronavirus disease 2019 (Covid-19) pandemic has highlighted the crucial role of randomized trials in guiding clinical practice and the need for designs that provide rapid evaluation of multiple interventions. Multigroup randomized clinical trials in which multiple experimental treatment groups are compared with a single control group allow for an efficient use of resources in that a separate control group does not need to be generated for each comparison.1 Platform trials are multigroup trials that permit experimental groups to enter and exit the trial at different times. However, it is important to remember that the unique evidentiary status of randomized trials is based on their ability to guarantee that the trial groups have (on average) equivalent patient populations that allow between-group differences in outcomes to be attributed to the intervention. This generally does not apply to designs that compare trial groups that include patients who did not undergo randomization concurrently.


  • Open Access

    Brain 18F-FDG PET of SIV-infected macaques after treatment interruption or initiation

    by William Schreiber-Stainthorp, Sanhita Sinharay, Sharat Srinivasula, Swati Shah, Jing Wang, Lori Dodd, H. Clifford Lane, Michele Di Mascio, Dima A. Hammoud

    Although rates of severe HIV-associated neurocognitive disorders have declined in the post-antiretroviral treatment (ART) era, subtle deficits persist, possibly exacerbated by treatment non-adherence. The actual effects of ART interruption/initiation on brain glucose metabolism as a reflection of viral replication and neuroinflammation remain unclear. Our study investigates how treatment initiation and interruption alter brain glucose metabolism in SIV-infected macaques, using 18F-FDG PET in correlation with plasma and CSF viral loads (VL) and cytokine levels. SIV-infected macaques (n = 7) underwent ART initiation only, ART interruption only, or both. Five uninfected animals served as controls. 18F-FDG PET imaging was performed at baseline and 1, 3, and 6 months after treatment modification. Mean and maximum standardized uptake values (SUV) for the whole-brain and subregions were calculated. Plasma and CSF VL and cytokine levels were measured. Paired t tests evaluated acute changes in whole-brain SUV from baseline to 1 month, while mixed-effect linear regression models evaluated changes over multiple timepoints and correlated SUV values with disease markers. ART interruption was associated with increased SUVmean and SUVmax acutely, after 1 month (SUVmean 95% CI [0.044–0.786 g/ml], p = 0.037; SUVmax 95% CI [0.122–3.167 g/ml], p = 0.041). The correlation between SUV and time, however, was not significant when evaluated across all timepoints. Increased SUVmean and SUVmax correlated with decreased CD4+ and CD8+ T-cell counts and increased plasma VL. SUVmax was positively associated with increases in CSF VL, and there were borderline positive associations between SUVmax and IL-2, and between SUVmean and IL-15. The treatment initiation group showed no associations between imaging and disease biomarkers despite viral suppression, reduced cytokine levels, and increased CD4+ and CD8+ T-cell counts. ART interruption is associated with increased brain glucose metabolism within 1 month of treatment cessation, which, in concert with increased levels of pro-inflammatory cytokines in the CSF, may reflect neuroinflammation in the setting of viral rebound. Although we cannot assert neurologic damage in association with cerebral hypermetabolism, it is a concerning outcome of ART non-adherence. Treatment initiation, meanwhile, did not result in significant changes in brain metabolism. HIV-induced neuroinflammation may require a longer period to abate than our follow-up period allowed.


  • Open Access

    A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma

    by Rhonda E. Colombo, Charles Fiorentino, Lori E. Dodd, Sally Hunsberger, Carissa Haney, Kevin Barrett, Linda Nabha, Richard T. Davey, Kenneth N. Olivier

    Influenza virus (IFV) infection is associated with increased morbidity and mortality in people with underlying lung disease. Treatment options for IFV are currently limited and antiviral resistance is a growing concern. DAS181, an inhaled antiviral with a unique mechanism of action, has shown promise in early clinical trials involving generally healthy human subjects. This study was undertaken to assess the safety and tolerability of DAS181 in individuals with underlying reactive airway disease. This was a randomized, double-blind, placebo-controlled, crossover phase 1 study of DAS181-F02. Dry particle inhaler administration of 10 mg was done on 3 consecutive days in ten adult volunteers with well-controlled asthma. The primary outcome was the frequency of adverse events (AEs), grade 1 or higher that occurred during each study period. There were 280 AEs among ten evaluable subjects (56.8 % active; 43.2 % placebo); 90.7 % were grade 1. No grade 3 or higher AEs occurred. A statistically significant association between exposure to DAS181 and experiencing any AE, a grade 1 AE, or a grade 2 AE was not detected. Overall, the majority of AEs were classified as possibly related (35.7 %), unlikely related (38.9 %), or unrelated (15.4 %) to study drug administration. However, there was a statistically significant association between exposure to DAS181 and experiencing a definitely or probably related AE. Respiratory effects, including dyspnea, dry cough, and chest discomfort related to respirations, accounted for all of the definitely related AEs and one of the most common probably related AEs. DAS181 was safe in this small study of otherwise healthy subjects with well-controlled asthma. However, the generalizability of these results is limited by the small sample size and generally mild nature of the subjects’ asthma at baseline. The increased association of respiratory events classified as probably or definitely related to DAS181 administration suggests caution may need to be employed when administering DAS181 to individuals with less stable reactive airway disease. Further investigation in a controlled setting of the safety and efficacy of DAS181 in a larger population of asthmatic subjects with varying disease activity is warranted. ClinicalTrials.gov NCT01113034 Trial Registration Date: April 27, 2010


  • Open Access

    Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012

    by Hongjo Choi, Myungsun Lee, Ray Y Chen, Youngran Kim, Soyoung Yoon, Joon Sung Joh, Seung Kyu Park, Lori E Dodd, Jongseok Lee, Taeksun Song, et al.

    Tuberculosis remains an important health concern in many countries. The aim of this study was to identify predictors of unfavorable outcomes at the end of treatment (EOT) and at the end of study (EOS; 40 months after EOT) in South Korea.